Lift Biosciences LtdLIfT BioSciences Ltd, active in London, Galway and Houston, has been awarded a grant of €12m from the Disruptive Technologies Innovation Fund (DTIF) to support the clinical translation of its Immuno-Modulatory Alpha Neutrophils (IMANs). This funding will enable the preparation of the world’s first allogeneic therapy using synthetically programmed neutrophil granulocytes for Phase I trials.
Tag Archive for: allogeneic cancer immunotherapy
Atara Biotherapeutics Inc. and Pierre Fabre SA announced the approval of Tabelecleucel, a therapy for a rare and potentially fatal malignancy.